Research graph
References from The correlation and auxiliary diagnostic value of gut microbiota and serological indicators with Kawasaki disease complicated by coronary artery lesions. Local targets link to admitted publications; unresolved targets remain external evidence.
Comparison of early characteristics of multisystemic inflammatory syndrome and Kawasaki disease in children and the course of Kawasaki disease in the pandemic
10.1186/s12887-024-04966-x · 2024 · External reference
Alterations in the gut mycobiome with coronary artery disease severity
10.1016/j.ebiom.2024.105137 · 2024 · External reference
The occurrence of coronary artery lesions in Kawasaki disease based on C-reactive protein levels: a retrospective cohort study
10.1186/s12969-021-00566-6 · 2021 · External reference
Correlation analysis of gut microbiota derivatives with coronary artery disease severity and prognosis
10.31083/rcm26566 · 2025 · External reference
CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease
10.1086/323155 · 2021 · External reference
Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review
10.3389/fimmu.2023.1237670 · 2023 · External reference
Predicting factors for refractory Kawasaki disease
10.4070/kcj.2010.40.5.239 · 2020 · External reference
The gut microbiota-host partnership as a potential driver of Kawasaki syndrome
10.3389/fped.2019.00124 · 2019 · External reference
Investigating the causal role of the gut microbiome in Kawasaki disease: mediating effects of immune cells
10.1007/s10067-025-07687-3 · 2025 · External reference
Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
10.1016/j.critrevonc.2019.09.003 · 2019 · External reference
Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease
10.1111/all.12558 · 2015 · External reference
Metagenomic analysis demonstrates distinct changes in the gut microbiome of Kawasaki diseases children
10.3389/fimmu.2024.1416185 · 2024 · External reference
The role of intestinal microbiota in cardiovascular disease
10.1111/jcmm.14195 · 2019 · External reference
Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association
10.1161/cir.0000000000001295 · 2024 · External reference
Our evolving understanding of Kawasaki disease pathogenesis: role of the gut microbiota
10.3389/fimmu.2020.01616 · 2020 · External reference
Bacterial induction of B cell senescence promotes age-related changes in the gut microbiota
10.1038/s41556-023-01145-5 · 2023 · External reference
Diagnosis, progress, and treatment update of Kawasaki disease
10.3390/ijms241813948 · 2023 · External reference
Gut microbiota-derived metabolites as key actors in inflammatory bowel disease
10.1038/s41575-019-0258-z · 2020 · External reference
Unusual presentation of Kawasaki disease with gastrointestinal and renal manifestations
10.2147/tcrm.s226624 · 2019 · External reference
Expression of oxidative stress and inflammatory indicators for coronary artery disease in Kawasaki disease
10.4084/mjhid.2024.052 · 2024 · External reference
Interleukin-35 enhances regulatory T cell function by potentially suppressing their transdifferentiation into a T helper 17-like phenotype in Kawasaki disease
10.1080/08820139.2023.2201283 · 2023 · External reference
Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition
10.1186/s12969-018-0303-4 · 2019 · External reference
Kawasaki disease may increase the risk of subsequent cerebrovascular disease
10.1161/strokeaha.120.032953 · 2022 · External reference
Case series on the efficacy and safety of tocilizumab in IVIG-resistant Kawasaki disease: A retrospective analysis of five patients
10.2147/jir.s479879 · 2024 · External reference
The intriguing link between the intestinal microbiota and cardiovascular disease
10.1055/s-0036-1597903 · 2017 · External reference
Assessment of vascular and endothelial function in Kawasaki disease
10.1016/j.bj.2022.03.010 · 2023 · External reference
Assessment of selected intestinal permeability markers in children with food allergy depending on the type and severity of clinical symptoms
10.3390/nu14204385 · 2022 · External reference
Kawasaki disease and multisystem inflammatory syndrome in children: common inflammatory pathways of two distinct diseases
10.1016/j.rdc.2023.03.002 · 2023 · External reference
Mechanism of HMGB1-RAGE in Kawasaki disease with coronary artery injury
10.1186/s40001-020-00406-5 · 2020 · External reference
The gut microbiota (microbiome) in cardiovascular disease and its therapeutic regulation
10.3389/fcimb.2022.903570 · 2022 · External reference
Kawasaki disease: an update
10.1007/s11926-020-00941-4 · 2020 · External reference
Implications of changing Z-score models for coronary artery dimensions in Kawasaki disease
10.1007/s00246-020-02501-0 · 2021 · External reference
Autoimmune aspects of Kawasaki disease
10.18176/jiaci.0300 · 2019 · External reference
Kawasaki disease: pathology, risks, and management
10.2147/vhrm.s291762 · 2022 · External reference
Kawasaki disease
10.1542/pir.2023-006051 · 2024 · External reference
Effects of changes on gut microbiota in children with acute Kawasaki disease
10.7717/peerj.9698 · 2020 · External reference
Prediction of coronary artery lesions based on C-reactive protein levels in children with Kawasaki disease: a retrospective cohort study
10.1016/j.jped.2023.02.005 · 2023 · External reference
The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis
10.1126/science.1241165 · 2013 · External reference
Interleukin-35 regulates peripheral T cell activity in patients with Kawasaki disease
10.1016/j.intimp.2021.107642 · 2021 · External reference
Unraveling the gut: the pivotal role of intestinal mechanisms in Kawasaki disease pathogenesis
10.3389/fimmu.2024.1496293 · 2024 · External reference
Epstein-Barr virus downregulates the α7 nicotinic acetylcholine receptor of CD8+ T lymphocytes might associate with coronary artery lesions in Kawasaki disease patients
10.1016/j.micinf.2023.105168 · 2023 · External reference
Dysbiosis of the gut microbiota as a susceptibility factor for Kawasaki disease
10.3389/fimmu.2023.1268453 · 2023 · External reference
Advances in understanding Kawasaki disease-related immuno-inflammatory response and vascular endothelial dysfunction
10.1002/ped4.12341 · 2022 · External reference
NLRP3 inflammasome: a novel insight into heart failure
10.1007/s12265-022-10286-1 · 2023 · External reference
Kawasaki disease: insights into the roles of T cells
10.3389/fimmu.2025.1582638 · 2025 · External reference
The reduced SCFA-producing gut microbes are involved in the inflammatory activation in Kawasaki disease
10.3389/fimmu.2023.1124118 · 2023 · External reference
Tocilizumab for the treatment of intravenous immunoglobulin-resistant Kawasaki disease in children: Two case reports and literature review
10.2147/jir.s603769 · 2026 · External reference
Activin a suppresses peripheral CD8+ T lymphocyte activity in acute-phase Kawasaki disease
10.1186/s12865-021-00407-x · 2021 · External reference
scRNA+TCR-seq reveals the pivotal role of dual receptor T lymphocytes in the pathogenesis of Kawasaki disease and during IVIG treatment
10.3389/fimmu.2024.1457687 · 2024 · External reference
Potential mechanisms and hypotheses for pathogenic microorganisms triggering Kawasaki disease
10.1007/s12016-025-09120-8 · 2025 · External reference
Alteration of the oral and gut microbiota in patients with Kawasaki disease
10.7717/peerj.15662 · 2023 · External reference
Factors affecting the duration of coronary artery lesions in patients with the Kawasaki disease: a retrospective cohort study
10.1186/s12969-021-00589-z · 2021 · External reference
